NCT02426723View on ClinicalTrials.gov

Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 19, 2015

Primary Completion Date

October 8, 2018

Study Completion Date

October 26, 2018

Conditions
Multiple Myeloma
Interventions
DRUG

Phase 1a: CWP232291

CWP232291 administered alone twice weekly every 4 weeks.

DRUG

Phase 1b: CWP232291, Lenalidomide, Dexamethasone

CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.

Trial Locations (4)

77030

The University of Texas MD Anderson Cancer Center, Houston

Unknown

Seoul National University Hospital, Seoul

Seoul St.Mary's Hospital, Seoul

Yonsei Severance Hospital, Seoul

Sponsors

Lead Sponsor

JW Pharmaceutical
All Listed Sponsors
lead

JW Pharmaceutical

INDUSTRY